cancer
-
Opportunity India Desk May 24 2022 - 3 min readGenes2Me has launched wide range of Next-Generation Sequencing (NGS)-based panels for oncology, personalised medicine, and hereditary diseases. According to the press note, by selectively targeting the clinically significant genes, these NGS panels enable comprehensive analysis with the most effective sequencing throughput. These panels have been designed and validated for all the common NGS platforms from ...
-
Franchise India Bureau Sep 26 2019 - 2 min readOnco, the cancer care aggregator, has secured $7 million in Series A funding round led by Accel Partners, Chiratae Ventures, and Dream Incubator. The fresh capital will be used by the company to boost its customer base and expand operations globally. Onco eyes to become a one-stop-shop for all cancer-related needs of patients and caregivers. Rashie ...
-
Franchise India Bureau Dec 26 2018 - 1 min readJP Nadda, Union Health Minister, has said that the largest cancer hospital in India, the National Cancer Institute in Haryana’s Jhajjar district, will be open to the public by the third week of January. The institute is being considered a landmark in the field of cancer research in India. It will lessen the deficit of ...
-
Franchise India Bureau Oct 19 2018 - 1 min readNovartis AG will acquire Endocyte Inc, a US-based cancer drugmaker, in an all-cash deal for $ 24 per share, or a total equity value of about $ 2.1 billion. This acquisition will expand the radiopharmaceuticals business of the Swiss drugmaker. The US-based firm said that the deal will help develop a broader role for radioligand ...
-
Franchise India Bureau Aug 06 2018 - 1 min readRegeneron Pharmaceuticals Inc has announced to invest $100 million in cancer drug developer bluebird bio Inc, and jointly the companies will develop new cell therapies for cancer. The investment will be at $238.10 per share, a premium of nearly 59 percent over bluebird's Friday closing price. Bluebird bio's shares were up about 7 pct at ...